Correction: Parallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay (PLoS ONE (2014) 9, 3 (e92801) DOI: 10.1371/journal.pone.0092801);Parallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Oran, Paul E ^a   Trenchevska, Olgica ^a   Nedelkov, Dobrin ^a   Borges, Chad R ^a   Schaab, Matthew R ^a   Rehder, Douglas S ^a   Jarvis, Jason W ^a   Sherma, Nisha D ^a   Shen, Luhui ^a   Krastins, Bryan ^b   Lopez, Mary F ^b   Schwenke, Dawn C ^c,d   Reaven, Peter D ^c   Nelson, Randall W ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b Thermo Fisher Scientific   (United States)

^c CARL T HAYDEN VA MEDICAL CENTER   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C; IGF1 PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ANTIBODY AFFINITY; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MASS SPECTROMETRIC IMMUNOASSAY; MASS SPECTROMETRY; MEASUREMENT PRECISION; POINT MUTATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; CLINICAL TRIAL; GENETICS; MALE; METABOLISM; PROCEDURES; TIME;

FEMALE; HUMANS; IMMUNOASSAY; INSULIN-LIKE GROWTH FACTOR I; MALE; POINT MUTATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS;

EID: 84899713259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095812     Document Type: Erratum

References (32)

1. Higashi Y, Sukhanov S, Anwar A, Shai SY, Delafontaine P (2010) IGF-1, oxidative stress and atheroprotection. Trends Endocrinol Metab 21: 245-254.
2. Hoppener JW, de Pagter-Holthuizen P, Geurts van Kessel AH, Jansen M, Kittur SD, et al. (1985) The human gene encoding insulin-like growth factor I is located on chromosome 12. Hum Genet 69: 157-160.
3. Brabant G, von zur Mühlen A, Wü ster C, Ranke MB, Kratzsch J, et al. (2003) Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 60: 53-60. (Pubitemid 36928670)
4. Rinderknecht E, Humbel RE (1978) The amino acid sequence of human insulinlike growth factor I and its structural homology with proinsulin. J Biol Chem 253: 2769-2776. (Pubitemid 8326483)
5. Merimee TJ, Laron Z (1996) Growth hormone, IGF-I and growth: new views of old concepts: Freund Pub.
6. Nilsson A, Isgaard J, Lindahl A, Dahlström A, Skottner A, et al. (1986) Regulation by growth hormone of number of chondrocytes containing IGF-I in rat growth plate. Science 233: 571-574. (Pubitemid 16019916)
7. Baserga R (1999) The IGF-I receptor in cancer research. Experimental cell research 253: 1-6.
8. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16: 143-163.
9. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocrine reviews 16: 3-34.
10. Laron Z (2001) Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol 54: 311-316.
11. Frystyk J, Freda P, Clemmons DR (2010) The current status of IGF-I assays - a 2009 update. Growth Horm IGF Res 20: 8-18.
12. Clemmons DR (2001) Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Hormone Research in Paediatrics 55: 73-79.
13. Krebs A, Wallaschofski H, Spilcke-Liss E, Kohlmann T, Brabant G, et al. (2008) Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population. Clin Chem Lab Med 46: 1776-1783.
14. de Kock SS, Rodgers JP, Swanepoel BC (2001) Growth hormone abuse in the horse: preliminary assessment of a mass spectrometric procedure for IGF'Äê1 identification and quantitation. Rapid communications in mass spectrometry 15: 1191-1197. (Pubitemid 32674841)
15. Bobin S, Popot M, Bonnaire Y, Tabet J (2001) Approach to the determination of insulin-like-growth-factor-I (IGF-I) concentration in plasma by high-performance liquid chromatography-ion trap mass spectrometry: use of a deconvolution algorithm for the quantification of multiprotonated molecules in electrospray ionization. Analyst 126: 1996-2001. (Pubitemid 33097132)
16. Nelson RW, Nedelkov D, Tubbs KA, Kiernan UA (2004) Quantitative mass spectrometric immunoassay of insulin like growth factor 1. Journal of Proteome Research 3: 851-855. (Pubitemid 39166247)
17. Thevis M, Thomas A, Schanzer W (2008) Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom Rev 27: 35-50. (Pubitemid 350279865)
18. Kay RG, Barton C, Velloso CP, Brown PR, Bartlett C, et al. (2009) Highthroughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration. Rapid Commun Mass Spectrom 23: 3173-3182.
19. Bystrom CE, Sheng S, Clarke NJ (2011) Narrow mass extraction of time-of-flight data for quantitative analysis of proteins: determination of insulin-like growth factor-1. Anal Chem 83: 9005-9010.
20. Kay R, Halsall DJ, Annamalai AK, Kandasamy N, Taylor K, et al. (2013) A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly. Clin Endocrinol (Oxf) 78: 424-430.
21. Borges CR, Rehder DS, Jarvis JW, Schaab MR, Oran PE, et al. (2010) Full-length characterization of proteins in human populations. Clin Chem 56: 202-211.
22. Trenchevska O, Kamcheva E, Nedelkov D (2010) Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms. J Proteome Res 9: 5969-5973.
23. Nelson RW, Krone JR, Bieber AL, Williams P (1995) Mass spectrometric immunoassay. Anal Chem 67: 1153-1158.
24. Oran PE, Jarvis JW, Borges CR, Sherma ND, Nelson RW (2011) Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. PROTEOMICS - Clinical Applications 5: 454-459.
25. Francis G, Ross M, Ballard F, Milner S, Senn C, et al. (1992) Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of molecular endocrinology 8: 213-223.
26. D'Aloisio AA, Schroeder JC, North KE, Poole C, West SL, et al. (2009) IGF-I and IGFBP-3 polymorphisms in relation to circulating levels among African American and Caucasian women. Cancer Epidemiol Biomarkers Prev 18: 954-966.
27. Kim JW, Park HM, Choi YK, Chong SY, Oh D, et al. (2011) Polymorphisms in genes involved in folate metabolism and plasma DNA methylation in colorectal cancer patients. Oncol Rep 25: 167-172.
28. Nedelkov D, Nelson RW, Kiernan UA, Niederkofler EE, Tubbs KA (2003) Detection of bound and free IGF-1 and IGF-2 in human plasma via biomolecular interaction analysis mass spectrometry. FEBS Lett 536: 130-134. (Pubitemid 36206419)
29. Passing H, Bablok (1983) A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 21: 709-720.
30. Bland JM, Altman DG (1999) Measuring agreement in method comparison studies. Stat Methods Med Res 8: 135-160. (Pubitemid 29425900)
31. Bystrom C, Sheng S, Zhang K, Caulfield M, Clarke NJ, et al. (2012) Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry. PLoS One 7: e43457.
32. Addona TA, Shi X, Keshishian H, Mani DR, Burgess M, et al. (2011) A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol 29: 635- 643.